Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
Ipsen announces the launch of an Employee Shareholding Plan
Ipsen announces late-breaking data from first head-to-head study comparing Dysport®...
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar...
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the...
Ipsen delivers strong sales in the first quarter of 2026...
Ojemda® approved in the European Union as the first targeted...
Ipsen announces that Beech Tree has obtained an exemption from...
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Ipsen appoints Michelle C. Werner as EVP, President of North...
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid...
Ipsen receives positive CHMP opinion for Ojemda® for the treatment...
You are now leaving the Ipsen group global website. To continue, please click on Continue?
How easy was it to navigate Ipsen website and locate the information you were seeking?
